CVS

Essential Facts About CVS Health

Shares of CVS Health have moved 1.4% today, and are now trading at a price of $74.64. In contrast, the S&P 500 index saw a 1.0% change. Today's trading volume is 4,587,394 compared to the stock's average volume of 7,453,263.

CVS Health Corporation provides health services in the United States. Based in Woonsocket, United States the company has 219,000 full time employees and a market cap of $96,047,783,936. CVS Health currently offers its equity investors a dividend that yields 3.2% per year.

The company is now trading -14.3% away from its average analyst target price of $87.09 per share. The 22 analysts following the stock have set target prices ranging from $74.0 to $104.0, and on average give CVS Health a rating of buy.

Over the last 12 months CVS shares have declined by -26.9%, which represents a difference of -43.1% when compared to the S&P 500. The stock's 52 week high is $101.88 per share and its 52 week low is $64.41. Based on CVS Health's average net margin growth of inf% over the last 6 years, its core business remains strong and the stock price may recover in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023 347,809,000 8,653,000 2 100.0
2022 322,467,000 4,327,000 1 -66.67
2021 292,111,000 8,001,000 3 0.0
2020 268,706,000 7,192,000 3 0.0
2019 256,776,000 6,634,000 3 inf
2018 194,579,000 -2,000 0
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS